Atlas Trials

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Clinical trial NCT07543250 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07543250
Sponsor
xuliang
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Breast Cancer
Start date
2026-05-16
Primary completion
2026-12-31
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.